The Tufts New England Regional Biosafety Laboratory (RBL) is available to regional investigators—including scientists from academia, not-for-profit organizations, industry and government—studying biodefense, infectious diseases, and emerging infectious diseases requiring biosafety level 3 (BSL-3) laboratories or animal (ABSL-3) accommodations.
The laboratory is located in Grafton Science Park, adjacent to the campus of the Tufts University Cummings School of Veterinary Medicine, in North Grafton, MA.
The Tufts New England RBL is able to serve investigators who require:
small animal models, including rodents, rabbits, ferrets, birds, and piglets
aerobiology and insectary capabilities
veterinary expertise and/or support services
Good Laboratory Practice (GLP) compliant studies
DOD BSAT studies
Please visit the Capabilities page for more specifics on the RBL.
If you would like more information about including the use of RBL facilities or services in your next funding application, please visit our Funding Resources page.
Current RBL investigators at the Cummings School, members of its highly regarded Department of Infectious Disease and Global Health (IDGH), have expertise in multiple Biodefense and Emerging Infectious Disease (BEID) categories; in particular, the biology, pathogenesis, immunopathology, pathophysiology, transmission, prevention, treatment and diagnosis of a wide spectrum of NIAID priority pathogens. Consultation with IDGH scientists is available to support the work of outside investigators.
Additional specific expertise includes:
Vaccine development and evaluation, including thermostable, micro-needle and needle-free delivery methods.
Development of animal models for the evaluation of vaccine candidates and therapeutics.
Development and preclinical evaluation of therapeutic and prophylactic agents.
Food and water security, involving development of sensitive detection methods for microorganisms.
Work at the RBL will focus on NIAID Category A, B, and C BSL-3 Priority Pathogens; researchers at the RBL and the Department of Infectious Disease and Global Health are experienced with the following diseases, pathogens and toxins, only some of which require BSL-3 containment:
Mycobacterium tuberculosis (TB), multi-drug resistant tuberculosis (MDR TB) and extensively drug resistant tuberculosis (XDR TB)
Staphylococcal enterotoxins (SE)
Clostridium difficile and related toxins
Shiga-toxin producing E. coli (STEC) and hemolytic uremic syndrome (HUS)
Shigella dysenteriae type 1; S. flexneri spp.; S. sonnei